Sponsor: Alliance for Clinical Trials in Oncology
Sponsor Study ID: A072201
Study Title: Randomized Phase II Trial of Anti-LAG-3 and Anti-PD-1 Blockade vs. SOC in Patients With Recurrent Glioblastoma
CTO #: 104132
NCT Number: NCT06325683
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Brain and Nervous System
Study Objectives: To compare the restricted mean survival time (RMST) for overall survival (OS) between patients receiving the combination of relatlimab (BMS-986016) and nivolumab versus patients receiving standard of care CCNU (lomustine).